Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell?

MRK trades near its 52-week high as Keytruda drives growth, while its pipeline and new products offer a path beyond the 2028 patent cliff.

Zacks Investment Research • 17 hours ago

Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference.

Business Wire • 20 hours ago

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It

Drug pricing is back on the front page, and healthcare investors have barely flinched. The White House's latest round of most-favored-nation pricing agreements brought nine more manufacturers into the fold, pushing the total to 26 companies covering 89% of the branded drug market.

MarketBeat • Sep 6, 2026

Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Merck (MRK) concluded the recent trading session at $150.32, signifying a -1.33% move from its prior day's close.

Zacks Investment Research • Sep 4, 2026

India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar

India's Cipla said on Thursday its U.S. unit entered an ​exclusive partnership with China's Qilu Pharmaceutical ‌to license a biosimilar version of Merck's cancer drug Keytruda for the U.S. ​market.

Reuters • Sep 3, 2026

Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold

Summit Therapeutics stock rocketed Thursday after its experimental cancer drug outperformed Merck's blockbuster, Keytruda.

Investors Business Daily • Sep 3, 2026

Why Is Merck (MRK) Up 18.2% Since Last Earnings Report?

Merck (MRK) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 3, 2026

Dogs Of The Dow: No Buys And Few Worth Watching

Dogs of the Dow remain generally overvalued, with none meeting the ideal 'fair price' threshold where dividends from $1K invested exceed share price. Analyst forecasts project 22.15% to 47.11% net gains for the top ten Dow Dogs by September 2027, with an average estimated gain of 28.46%. Yield-based strategies favor underdogs, but current market conditions suggest waiting for significant price pullbacks or dividend increases to achieve optimal entry points.

Seeking Alpha • Sep 3, 2026

Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference.

Business Wire • Sep 2, 2026

Why Moderna's Cancer Vaccine Matters to Investors

Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.

ETF Trends • Sep 2, 2026